Assessment of the Mechanism for Remdesivir-Associated Clinical ALT Elevations Using DILIsym Quantitative Systems Toxicology Modeling

Authors: Yang K
Conference: SLP MIDD+
Software: DILIsym®
Division: DILIsym Services


• Remdesivir, a monophosphoramidate prodrug of a nucleoside analog, has been granted Emergency Use Authorization in the U.S. for the treatment of hospitalized COVID-19 patients.
• In a Ph1 clinical study in healthy volunteers treated with the 150 mg daily dose of remdesivir for 7 or 14 days (higher than the current clinical dose) [1], reversible low- grade elevations of serum ALT and AST were observed at 5-25 days after the first dose in 8 out of 16 individuals.

By Kyunghee Yang

Download Poster

Presented at SLP MIDD+ Virtual Conference March 3-4, 2021